Repeated naloxone administration in schizophrenia: A phase II world health organization study

D. Pickar; W. E. Bunney; P. Douillet; B. B. Sethi; M. Sharma; M. E. Vartanian; R. P. Lideman; D. Naber; K. Leibl; I. Yamashita; T. Koyama; W. M A Verhoeven; F. Vartanian; P. V. Morozov; T. Ngo Khac

doi:10.1016/0006-3223(89)90197-2

Repeated naloxone administration in schizophrenia: A phase II world health organization study

D. Pickar, W. E. Bunney, P. Douillet, B. B. Sethi, M. Sharma, M. E. Vartanian, R. P. Lideman, D. Naber, K. Leibl, I. Yamashita, T. Koyama, W. M A Verhoeven, F. Vartanian, P. V. Morozov, T. Ngo Khac

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

In the context of a previous WHO collaborative study, six research centers reported that naloxone (0.3 mg/kg) produced significant improvement in symptomatology in neuroleptictreated patients. In the current Phase II WHO study, repeated (4 days) naloxone (0.3 mg/kg) administration was performed in schizophrenic patients (n = 43) from five WHO collaborating centers using a double-blind, placebo-controlled design. Both naloxone and placebo administrations were associated with significant reductions in symptoms. Naloxone, however, was not superior to placebo. These data are discussed in relation to endorphin hypotheses of schizophrenia.

Original language	English (US)
Pages (from-to)	440-448
Number of pages	9
Journal	Biological Psychiatry
Volume	25
Issue number	4
DOIs	https://doi.org/10.1016/0006-3223(89)90197-2
State	Published - Feb 15 1989
Externally published	Yes

ASJC Scopus subject areas

Biological Psychiatry

Access to Document

10.1016/0006-3223(89)90197-2

Cite this

Pickar, D., Bunney, W. E., Douillet, P., Sethi, B. B., Sharma, M., Vartanian, M. E., Lideman, R. P., Naber, D., Leibl, K., Yamashita, I., Koyama, T., Verhoeven, W. M. A., Vartanian, F., Morozov, P. V., & Khac, T. N. (1989). Repeated naloxone administration in schizophrenia: A phase II world health organization study. Biological Psychiatry, 25(4), 440-448. https://doi.org/10.1016/0006-3223(89)90197-2

Pickar, D, Bunney, WE, Douillet, P, Sethi, BB, Sharma, M, Vartanian, ME, Lideman, RP, Naber, D, Leibl, K, Yamashita, I, Koyama, T, Verhoeven, WMA, Vartanian, F, Morozov, PV & Khac, TN 1989, 'Repeated naloxone administration in schizophrenia: A phase II world health organization study', Biological Psychiatry, vol. 25, no. 4, pp. 440-448. https://doi.org/10.1016/0006-3223(89)90197-2

@article{49a53fceb72648ff9033aa2e8c8b0677,

title = "Repeated naloxone administration in schizophrenia: A phase II world health organization study",

abstract = "In the context of a previous WHO collaborative study, six research centers reported that naloxone (0.3 mg/kg) produced significant improvement in symptomatology in neuroleptictreated patients. In the current Phase II WHO study, repeated (4 days) naloxone (0.3 mg/kg) administration was performed in schizophrenic patients (n = 43) from five WHO collaborating centers using a double-blind, placebo-controlled design. Both naloxone and placebo administrations were associated with significant reductions in symptoms. Naloxone, however, was not superior to placebo. These data are discussed in relation to endorphin hypotheses of schizophrenia.",

author = "D. Pickar and Bunney, {W. E.} and P. Douillet and Sethi, {B. B.} and M. Sharma and Vartanian, {M. E.} and Lideman, {R. P.} and D. Naber and K. Leibl and I. Yamashita and T. Koyama and Verhoeven, {W. M A} and F. Vartanian and Morozov, {P. V.} and Khac, {T. Ngo}",

year = "1989",

month = feb,

day = "15",

doi = "10.1016/0006-3223(89)90197-2",

language = "English (US)",

volume = "25",

pages = "440--448",

journal = "Biological Psychiatry",

issn = "0006-3223",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Repeated naloxone administration in schizophrenia

T2 - A phase II world health organization study

AU - Pickar, D.

AU - Bunney, W. E.

AU - Douillet, P.

AU - Sethi, B. B.

AU - Sharma, M.

AU - Vartanian, M. E.

AU - Lideman, R. P.

AU - Naber, D.

AU - Leibl, K.

AU - Yamashita, I.

AU - Koyama, T.

AU - Verhoeven, W. M A

AU - Vartanian, F.

AU - Morozov, P. V.

AU - Khac, T. Ngo

PY - 1989/2/15

Y1 - 1989/2/15

N2 - In the context of a previous WHO collaborative study, six research centers reported that naloxone (0.3 mg/kg) produced significant improvement in symptomatology in neuroleptictreated patients. In the current Phase II WHO study, repeated (4 days) naloxone (0.3 mg/kg) administration was performed in schizophrenic patients (n = 43) from five WHO collaborating centers using a double-blind, placebo-controlled design. Both naloxone and placebo administrations were associated with significant reductions in symptoms. Naloxone, however, was not superior to placebo. These data are discussed in relation to endorphin hypotheses of schizophrenia.

AB - In the context of a previous WHO collaborative study, six research centers reported that naloxone (0.3 mg/kg) produced significant improvement in symptomatology in neuroleptictreated patients. In the current Phase II WHO study, repeated (4 days) naloxone (0.3 mg/kg) administration was performed in schizophrenic patients (n = 43) from five WHO collaborating centers using a double-blind, placebo-controlled design. Both naloxone and placebo administrations were associated with significant reductions in symptoms. Naloxone, however, was not superior to placebo. These data are discussed in relation to endorphin hypotheses of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=0024536473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024536473&partnerID=8YFLogxK

U2 - 10.1016/0006-3223(89)90197-2

DO - 10.1016/0006-3223(89)90197-2

M3 - Article

C2 - 2539206

AN - SCOPUS:0024536473

SN - 0006-3223

VL - 25

SP - 440

EP - 448

JO - Biological Psychiatry

JF - Biological Psychiatry

IS - 4

ER -

Repeated naloxone administration in schizophrenia: A phase II world health organization study

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this